These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 48882)

  • 1. Letter: Analogues of growth-hormone release-inhibiting hormone.
    Evered DC; Gomez-Pan A; Tunbridge WM; Hall R; Lind T; Besser GM; Mortimer CH; Thorner MO; Schally AV; Kastin AJ; Coy DH
    Lancet; 1975 May; 1(7918):1250. PubMed ID: 48882
    [No Abstract]   [Full Text] [Related]  

  • 2. Medical therapy with somatostatin analogues for acromegaly.
    Sassolas G
    Eur J Endocrinol; 1995 Dec; 133(6):675-7. PubMed ID: 8548050
    [No Abstract]   [Full Text] [Related]  

  • 3. Dissociated effects of somatostatin analogs on arginine-induced insulin, glucagon and growth hormone release in acromegalic patients.
    Wajchenberg BL; Cesar FP; Leme CE; Borghi VC; Souza VC; Souza IT; Neto DG; Germek OA; Coy DH; Comaru-Schally AM
    Horm Metab Res; 1983 Oct; 15(10):471-4. PubMed ID: 6139329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical applications of somatostatin analogs.
    Marbach P; Neufeld M; Pless J
    Adv Exp Med Biol; 1985; 188():339-53. PubMed ID: 2863941
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined treatment of somatostatin analogues with pegvisomant in acromegaly.
    Franck SE; Muhammad A; van der Lely AJ; Neggers SJ
    Endocrine; 2016 May; 52(2):206-13. PubMed ID: 26661938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Response of growth hormone to the acute test using GH-releasing factor 1-29 in acromegaly. Comparison in the baseline situation and under treatment with prolonged-action somatostatin].
    Gavilán I; Santos C; García-Luna PP; Acosta D; Leal-Cerro A; Navarro E; Fernández-López I; Astorga R
    Rev Clin Esp; 1988 Mar; 182(4):187-91. PubMed ID: 2901136
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacological options in the treatment of acromegaly.
    Ezzat S
    Curr Opin Investig Drugs; 2005 Oct; 6(10):1023-7. PubMed ID: 16259223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of high dose somatostatin analogue on growth hormone concentrations in acromegaly.
    Sandler LM; Burrin JM; Joplin GF; Bloom SR
    Br Med J (Clin Res Ed); 1988 Mar; 296(6624):751-2. PubMed ID: 2894886
    [No Abstract]   [Full Text] [Related]  

  • 9. Somatostatin: a review of its effects especially in human beings.
    Hansen AP; Lundbaek K
    Diabete Metab; 1976 Dec; 2(4):203-18. PubMed ID: 190058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Medical treatment of acromegaly. Somatostatin analogs offer a real hope].
    Kuhn JM; Héron I
    Rev Prat; 1992 Nov; 42(18):2303-7. PubMed ID: 1363585
    [No Abstract]   [Full Text] [Related]  

  • 11. Somatuline LA: a new treatment for acromegaly.
    Bouloux PM
    Hosp Med; 1998 Aug; 59(8):642-5. PubMed ID: 9829060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Advancing acromegaly with low growth hormone levels. Influence of an analog of somatostatin administered in continuous subcutaneous infusion].
    Leblanc H; Lebouc Y; Saltiel H; Thote A; Passa P
    Presse Med; 1988 Feb; 17(4):164. PubMed ID: 2894669
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacological studies of somatostatin and somatostatin-analogues: therapeutic advances and perspectives.
    Moreau JP; DeFeudis FV
    Life Sci; 1987 Feb; 40(5):419-37. PubMed ID: 2880272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995.
    N Engl J Med; 1986 May; 314(21):1390-2. PubMed ID: 2871490
    [No Abstract]   [Full Text] [Related]  

  • 15. Selective inhibitory effect of the analog D5-F-TrP8-D-Cys14 somatostatin on the arginine induced release of insulin, growth hormone and glucagon, in normal human beings.
    González-Bárcena D; Mendoza F; Graef A; Medina R; Comaru-Schally AM; Schally AV
    Arch Invest Med (Mex); 1985; 16 Suppl 3():105-14. PubMed ID: 2878649
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination treatment with somatostatin analogues and pegvisomant in acromegaly.
    Neggers SJ; van der Lely AJ
    Growth Horm IGF Res; 2011 Jun; 21(3):129-33. PubMed ID: 21498099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term treatment of acromegaly with a somatostatin analog].
    Vest S
    Ugeskr Laeger; 1987 Aug; 149(34):2263. PubMed ID: 2897734
    [No Abstract]   [Full Text] [Related]  

  • 18. [100 years of acromegaly: general lessons about a rare disease].
    Lamberts SW
    Ned Tijdschr Geneeskd; 1986 May; 130(20):902-4. PubMed ID: 2873513
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical implications of growth hormone release inhibiting hormone (GH-RIH).
    Besser GM
    Curr Top Mol Endocrinol; 1976; 3():115-25. PubMed ID: 211004
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition of frusemide-induced hyperreninaemia by growth-hormone release-inhibiting hormone in man.
    Rosenthal J; Raptis S; Escobar-Jimenez F; Pfeiffer EF
    Lancet; 1976 Apr; 1(7963):772-4. PubMed ID: 56589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.